Fueled by surging digital pathology partnerships, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs, the precision medicine field is evolving rapidly.
Be the first to access our new event program: https://ter.li/5c0adwgh
Join industry-leading peers from biopharma, diagnostics, testing labs, and regulatory bodies, to unpack fit-for-purpose CDx strategies, spark new co-development partnerships, discover cutting-edge genomic sequencing, pathology, multi-omic, single cell and multimodal innovations.
This year’s agenda will expand to five dedicated tracks of content to ensure your entire team leave equipped with the tools and insights to tackle the specific challenges facing them at their stage of development.
- Biomarker Discovery & Translation
- Clinical & CDx Development
- Rx-Dx Commercialization & Adoption
- Digital Pathology & Spatial Biomarkers (BRAND-NEW)
- Multimodal & AI‑Enabled Endpoints (BRAND-NEW)
Grasp the opportunity to attend the industry’s leading touchpoint for drug-diagnostic co-development advancement.
Together let’s translate promising precision medicine into scalable, equitable drug-diagnostic therapies for patients across oncology, neurological, autoimmune, rare and chronic diseases.
Sign up today: https://ter.li/0jb66uvu
Registration is FREE* for drug developers and researchers.
*Subject to terms and conditions visit the website to learn more.